10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Thursday, 2026-02-12. Here’s what investors need to know before the announcement.
Analysts estimate that 10x Genomics will report an earnings per share (EPS) of $-0.10.
The market awaits 10x Genomics’s announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It’s important for new investors to understand that guidance can be a significant driver of stock prices.
Historical Earnings Performance
Last quarter the company missed EPS by $0.07, which was followed by a 17.31% increase in the share price the next day.
Here’s a look at 10x Genomics’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.15 | -0.19 | -0.29 | -0.11 |
| EPS Actual | -0.22 | 0.28 | -0.28 | -0.40 |
| Price Change % | 17.00 | -4.00 | 2.00 | -1.00 |
10x Genomics Share Price Analysis
Shares of 10x Genomics were trading at $19.15 as of February 10. Over the last 52-week period, shares are up 57.66%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Opinions on 10x Genomics
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on 10x Genomics.
With 8 analyst ratings, 10x Genomics has a consensus rating of Neutral. The average one-year price target is $20.0, indicating a potential 4.44% upside.
Understanding Analyst Ratings Among Peers
The following analysis focuses on the analyst ratings and average 1-year price targets of Adaptive Biotechnologies, Azenta and Fortrea Holdings, …